Spinal Cord Injury - Pipeline Insight, 2025

This “Spinal Cord Injury - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Spinal Cord Injury: Understanding

Spinal Cord Injury: Overview

Spinal cord injury is defined as traumatic damage to the spinal cord or nerves at the end of the spinal canal. This affects the conduction of sensory and motor signals across the site of the lesion. Spinal cord injury is a debilitating neurological condition with tremendous socioeconomic impact on affected individuals and the health care system. Spinal cord injury are two types: incomplete and complete injury. Spinal cord injury (SCI) is a serious medical condition that causes functional, psychological and socioeconomic disorder. Patients with SCI experience significant impairments in various aspects of their life.

Spinal cord injury (SCI) causes temporary or permanent loss of motor, sensory, or autonomic function below the injury site, with severity depending on the level and extent of damage. Symptoms include paralysis (quadriplegia or paraplegia), loss of sensation, bladder/bowel dysfunction, and autonomic issues like blood pressure instability, sacral spine injury. Complete injuries result in total function loss, while incomplete injuries preserve some function. High cervical injuries may impair breathing, making early intervention crucial. There are two main types of Spinal Cord Injury based on severity:

Incomplete Injury: Partial preservation of motor or sensory function below the injury level. Types include conditions like anterior cord syndrome, Brown-Séquard syndrome, central cord syndrome, and posterior cord syndrome.

Complete Injury: Total loss of motor and sensory function below the injury level and no communication between the brain and the spinal cord below the injury.

The spinal cord (SC) has three major functions in human beings: sensibility, autonomous control, and motor control. Destructive mechanisms following SCI can have grave consequences on these functions. The pathophysiology of SCI can be divided into primary and secondary damage based on the self-destructive mechanisms following initial injury. Acute phase is characterized by ionic changes, which interrupt nerve impulses and lead to edema; the subacute phase involves a series of events including ischemia, vasospasm, thrombosis, inflammatory response, free radicals (FR) production, lipid peroxidation (LP), and the activation of autoimmune responses resulting in apoptosis. Chronic phase all the auto destructive mechanisms generated during the acute and sub-acute phase increase and demyelination processes are triggered, alongside the formation of a glial scar, which hinders axonal regeneration

The diagnosis of spinal cord injuries involves assessing neurological damage, residual function, and complications, with imaging playing a key role. MRI is the gold standard for evaluating the spinal cord, ligaments, discs, and soft tissues, with sagittal T2 MRI sequences being particularly useful for prognosis. Individuals with spinal cord injuries or disorders require multidisciplinary care management to achieve optimal health outcomes. Treatments for chronic SCI focus on avoiding or improving characteristic pathophysiological mechanisms, such as glial scar formation, demyelination, and astrogliosis. Treatment strategies for acute SCI are limited to preventing further damage, therapeutic strategies for chronic SCI instead focus on promoting neuronal regeneration and treating accompanying symptoms of chronic complications. Treatment for chronic SCI can be classified into Pharmacological and non-pharmacological therapies.

"Spinal Cord Injury - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spinal Cord Injury pipeline landscape is provided which includes the disease overview and Spinal Cord Injury treatment guidelines. The assessment part of the report embraces, in depth Spinal Cord Injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal Cord Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Spinal Cord Injury R&D. The therapies under development are focused on novel approaches to treat/improve Spinal Cord Injury.

Spinal Cord Injury Emerging Drugs Chapters

This segment of the Spinal Cord Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spinal Cord Injury Emerging Drugs

ES-1601: EUSOL Biotech Co., Ltd.

ES135 is a recombinant human acid fibroblast growth factor (rhFGF1) with 135 amino acids. Its indication for spinal cord injury has been investigated in approximately total 300 patients in phase 1, 2 and 3 clinical trials, respectively. Currently, it is being tested in an exploratory clinical trial in patients with carpal tunnel syndrome for new indication of peripheral nerve injury. Currently the drug is in Phase III stage of its development of spinal cord injury.

• MT-3921: Mitsubishi Tanabe Pharma Corporation

DB102 (enzastaurin) Based on the results of fundamental research by Professor Yamashita’s research team, MT-3921 is a humanized anti-RGMa antibody jointly developed by MTPC and Osaka University since 2005. Current research concluded that RGMa is associated with inhibition of neuronal survival and neuroregeneration, involved in the progression of inflammation, and may play a role in neurological diseases including spinal cord injury, stroke, and multiple sclerosis. The data from the preclinical animal studies conducted by Professor Yamashita’s research team and MTPC indicate that treatment with MT-3921 improves locomotor function and promotes neurodegeneration. Currently the drug is in Phase II stage of its development for spinal cord injury.

NVG-291: NervGen

NVG-291, is an inhibitor of protein tyrosine phosphatase sigma and has the potential as a therapeutic for diseases where there is nerve damage, either as a result of injury, neurodegenerative disease, or other causes. PTPσ inhibition has been evaluated preclinically in models of spinal cord injury, multiple sclerosis, myocardial ischemia, stroke and other diseases using NVG-291-R. NVG-291-R is a close analog to NVG-291 and works via the same target. In the literature, NVG-291-R is commonly referred to as intracellular signaling peptide, or ISP. Currently, the drug is in the Phase I/II stage of its development for the treatment of Chronic Spinal Cord Injury.

Spinal Cord Injury: Therapeutic Assessment

This segment of the report provides insights about the different Spinal Cord Injury drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Spinal Cord Injury

There are approx. 25+ key companies which are developing the therapies for Spinal Cord Injury. The companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. Phase III include, EUSOL Biotech Co., Ltd.

Phases

The report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spinal Cord Injury: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal Cord Injury therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal Cord Injury drugs.

Spinal Cord Injury Report Insights

• Spinal Cord Injury Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spinal Cord Injury Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Spinal Cord Injury drugs?
• How many Spinal Cord Injury drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinal Cord Injury?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spinal Cord Injury therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spinal Cord Injury and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• EUSOL Biotech Co., Ltd.
• Kringle Pharma
• Mitsubishi Tanabe Pharma Corporation
• Lineage Cell Therapeutics
• NervGen Pharma
• AlaMab therapeutics
• Axonis Therapeutics
• NurExone Biologic

Key Products

• ES-1601
• KP-100IT
• MT-3921
• OPC1
• NVG-291
• ALMB0166
• AXN-027
• ExoPTEN

This product will be delivered within 1-3 business days.